Jon Faldasz: Ondansetron May Have Cardiotoxicity Risk Among 5-HT3RAs Due to High Concentration in Cardiac Tissues
Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:
”Just dropped: Ondansetron may have outstanding cardiotoxicity risk among 5-HT3RAs due to high concentration in cardiac tissues
Published today in Nature Scientific Reports, Cai et al used the FDA’s Adverse Event Reporting System (FAERS) to review records of cardiotoxicity associated with 5-HT3RA use. They found:
– The different 5-HT3RAs exhibit varying degrees and types of cardiotoxicity
– QT prolongation was most common for ondansetron (granisetron was least common)
– In a subsequent PBPK model extrapolation they estimated that ondansetron concentrations in cardiac tissue were 2.3x higher than plasma.
They suggested that providers might “prioritize low cardiac toxicity 5-HT3RAs” (read: avoid ondansetron) in patients with heart disease.
For my part, FAERS seems like an untapped resource for this type of work, now I’m thinking on what other investigations could make use of it.
Article reference here.”
Title: Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study
Authors: Yijun Cai, Shaohong Luo, Shen Lin, Xiaoting Huang, Xiangzhen Wang, Lijing Yang, Xiongwei Xu, Xiuhua Weng
Stay updated with Hemostasis Today.
-
May 27, 2026, 13:10Amos Gitonga M: Global Partnerships Supporting Hemophilia and Sickle Cell Care in Africa
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK